Market News

Amylyx (NASDAQ:AMLX) Jumps on Backing for ALS Treatment from FDA Advisory Committee

Shares of clinical-stage biotechnology company Amylyx Pharmaceuticals (NASDAQ:AMLX) are up today after its Amyotrophic Lateral Sclerosis (ALS) treatment AMX0035 received favorable votes (7:2) from the U.S. Food and Drug Administration’s (FDA) advisory committee for approval.

The treatment had received a priority review in December 2021 and a final decision on approval is expected by September 29.

If AMX0035 gets an approval, it will be the first ALS treatment that has shown a substantial “slowing of disease progression and functional decline, as well as extended survival in a randomized, placebo-controlled clinical trial.”

ALS is a progressive and fatal neurodegenerative disorder. AMX0035 is currently conditionally approved in Canada as Albrioza for the treatment of ALS.

Is AMLX Stock a Good Buy?

On the back of these developments, AMLX has scored three Buy ratings today. Overall, the stock has a Strong Buy consensus rating with an average price target of $43.25. This indicates a 55.3% potential upside.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More